Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Baltic Dry Index: BDIY. Is there a better source than Bloomberg to get a daily quote for this? They aren't very timely when it comes to updates.
Thanks
Murocman
Thanks...will take a look.
Murocman
And what report would that be. If you look waaaay back to the beginning of Feb and take a look at the chart, you'll notice the stock was at $4. Then came this event called a data release and their trial was a FAILURE! My only question was what makes anyone think that anything has changed to have any hope of the stock ever getting back to that level let alone warranting the current valuation, because I don't see it.
Good luck
There trial failed and the stock tanked. What is new that makes this a compelling investment?
Murocman
Was burned here on their trial failure. What has changed that would make this a compelling buy?
Murocman
CATB. Volume and price spike today coinciding with the Oppenheimer presentation. Wonder what they said?
Murocman
Volume and price spike today coinciding with the Oppenheimer presentation. Wonder what they said?
Murocman
PIRS Moving on volume with no news.
Murocman
Anybody worried about a cash raise before data? Looked like they only had $7m in cash as of 12/31/16 per their latest corporate presentation dated Feb 17.
Murocman
No...they will still have to run a pivotal registration trial. I'd also be surprised if the company released the data before it is released to the public. They got fast track on the strength of the public data released to date IMO.
GLTA,
Murocman
According to their latest corporate presentation, they aren't projecting an NDA until Q3, 2018.
If that holds, we're probably at least two years away from this being approved for use.
Murocman
Thanks....nice!
Murocman
Who is 'nea'?
Murocman
Yes, I expect tomorrow or Tuesday based on past history.
Murocman
Agreed. Having no debt is a huge plus for the bottom line. Price action is good today. Just need some volume to come in.
Murocman
Thanks for the DD. Really thinking that a good report will be a springboard to differentiate this company from "all the others" in the shipping sector. One quarter can be a fluke but two and a positive outlook should do wonders for the share price.
As mentioned previously, as long as they continue to emphasize the inland transport booking, they should be set up well to keep the momentum going.
Murocman
Found this digging around tonight:
Sino-Global Shipping America, Ltd. (NASDAQ:SINO) COO Zhi Kang Huang sold 90,000 shares of Sino-Global Shipping America stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $2.84, for a total transaction of $255,600.00. Following the sale, the chief operating officer now directly owns 80,000 shares of the company’s stock, valued at approximately $227,200. The sale was disclosed in a document filed with the SEC,
I know insiders sell for many reasons, but reducing holdings by over half is not necessarily what you would like to see a month before earnings are due.
GLTA,
Murocman
Must be some kind of institutional trading adjustment?
At any rate, long and strong and looking forward to a good report early next week!
Murocman
Dipping this morning based on DRYS earnings after the bell yesterday. If it can re-bound quickly or hold firm, that would be a good sign.
Murocman
Agreed. Looking at their last 10Q, as long as they continued to focus more on revenue generation from inland transportation vice oceanic shipping services, I think they stand a good chance of keeping the momentum going. It looks like that's the way they want to develop the business and connect shippers with their growing inland network via the website. Looking for $6-8 on good news. We should see more volume and upward price movement mid-late week.
GLTA,
Murocman
Should see earnings reported next Monday or Tuesday based on past history. Looking for a run-up mid-late week and hopefully a nice pop on release like occurred in Nov 16.
GLTA,
Murocman
According to date for last year's filing should be mid-Feb, for Q2. Hopefully it will be a nice catalyst.
Murocman
It probably won't move much until they meet with the FDA. If there ends up being something salvageable off the secondary end points, it may pop some.
Murocman
I'm with you. I hate when companies do this. Have been burned much more than rewarded.
Keeping a toe in the water here only and may look to play the bounce if news is good and there is the opportunity to do so.
Murocman
The "good news" here is that this is an already approved drug with very good efficacy data around the world. There is also very good institutional ownership (quality and quantity) for the stock.
Those things are why I'm here. Still nerve wracking nonetheless.
Murocman
Always nerve wracking when a company waits until the last minute to release data. I've had a few of these and the data has been bad.
Murocman
A lot of small cap bios perked up today mid-day and closed strong on good volume. Anybody know of any news that would have caused the sector to wake up?
Murocman
Very impressive action today. If it can follow-through tomorrow, the chart looks open to the $4 range.
Murocman
Trial data but that's not supposed to be until April'ish.
Murocman
Good points all. Am hoping for $4-6 as well.
Murocman
Agreed that the price-volume action is not promising. The only thing I'd offer is that AQXP did the same thing before they released results and the stock skyrocketed from the $2 range to a peak of $55 in two trading days. They had even telegraphed that the data would be good.
Not sure what to think here. The history of the drug says this should be positive but you never know and this company is more or less a one trick pony, so lots of risk if they fail.
Murocman
Gotten a little ugly here the yesterday and so far today from a price-volume standpoint.
I think it's a function of getting down to the wire for getting results out in January and maybe some thought they may not be so good if the company is waiting until the end of the month to release results.
Murocman
Yes very nice price action and good volume as well.
Murocman
Last year they did not report Q4 and full year earnings until 31 March. Wouldn't be surprised to see that again as many companies delay their Q4/full year to the 90 days allowed by the SEC.
Murocman
CATB Catalyst play into mid Feb
Top line Phase II Data for DMD due by mid-Feb
http://ir.catabasis.com/phoenix.zhtml?c=251269&p=irol-calendar
Heavily owned by Institutions:
https://finance.yahoo.com/quote/CATB/holders?p=CATB
Mkt Cap of around $84M
Chart looks excellent:
http://stockcharts.com/h-sc/ui?s=catb
Definitely worth a look IMO.
Murocman
I'd agree with that. Maybe that and some news on the first MACI procedure will be the tonic that reverses the very disappointing price action we've had since approval.
I know that's been mainly due the dilution but I think there is also a lack of confidence in management's ability to execute that's keeping buyers away. will need some good news on the execution front to change that.
I was in deep for approval, and got out with a much smaller profit than I expected. Might dip a toe or two but mostly watching until this company proves it can run a business.
GLTA,
Murocman
Is there a specific event coming for the 24 week data, or will it likely just be a PR by the company?
TIA,
Murocman
Nice to see it moving so well on heavy volume with no news. Hopefully the data release will support this shooting much higher. I think we could see around $6 per share on good Ph III data.
GLTA,
Murocman
TENX. Volume alert. Moving higher on very heavy volume. No news yet but Ph III trial data for their cardiac drug due any day.
GLTA,
Murocman
Q2 earnings mid Feb looks like? May serve as a nice catalyst.
Murocman